New PCR Screen Boosts Detection of Growth Hormone Peptides in Horses

In competitive equine sports, the use of performance-enhancing drugs (PEDs) poses a significant challenge to fair play. Among these, growth-hormone-releasing hormone (GHRH) analogs, such as CJC-1295, are particularly concerning due to their anabolic effects and difficulty in detection. Current testing methods often lack the required sensitivity and specificity to catch these substances. This study addresses the critical need for more robust and sensitive analytical techniques to detect GHRH analogs in equine plasma, ensuring integrity in racing and equestrian events.

The developed IPCR method demonstrated exceptional sensitivity and specificity for CJC-1295 and related GHRH analogs in equine plasma. It achieved a remarkable detection limit of 0.5 picograms per milliliter (pg/mL) for CJC-1295, representing a 10-fold improvement over conventional ELISA methods. The assay exhibited 98% specificity, showing no significant cross-reactivity with structurally similar peptides or endogenous equine compounds. > The developed IPCR method achieved a detection limit of 0.5 pg/mL for CJC-1295 in equine plasma, demonstrating superior sensitivity compared to existing methods. Furthermore, the method maintained 95% sensitivity across a panel of 5 different GHRH analogs tested, and successfully detected CJC-1295 in spiked samples up to 72 hours post-simulated administration, significantly extending the detection window.